Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.56 |
| ▸ | GHSR | Q92847 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969045 | 0.80 | BRD4 (0.49) | BRD4GHSRPOLBCASP6KMT2A | |
| SCHEMBL3971829 | 0.76 | POLB (0.56) | BRD4GHSRPOLBCASP6KMT2A | |
| SCHEMBL4590137 | 0.75 | KMT2A (0.65) | BRD4GHSRPOLBCASP6KMT2A | |
| SCHEMBL15630078 | 0.73 | POLB (0.71) | BRD4POLBCASP6KMT2A | |
| SCHEMBL3968785 | 0.73 | MEN1 (0.53) | BRD4GHSRPOLBCASP6KMT2A | |
| SCHEMBL4590397 | 0.72 | KMT2A (0.59) | BRD4POLBCASP6KMT2A | |
| SCHEMBL16107891 | 0.72 | BRD4 (1.00) | BRD4 | |
| SCHEMBL3967991 | 0.72 | ADAMTS5 (0.52) | BRD4GHSRPOLBCASP6KMT2A | |
| SCHEMBL2498528 | 0.72 | BRD4 (0.57) | BRD4POLBCASP6KMT2AHTR6 | |
| SCHEMBL122043 | 0.72 | SCN9A (0.40) | BRD4GHSRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202871-B2 | Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-19 | — | — | US | disclosed |
| EP-2188253-B1 | Indol-2-one derivatives disubstituted in 3-position, preparation thereof and therapeutic use thereof | SANOFI SA (FR) | 2012-03-07 | — | — | EP | disclosed |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| EP-2188253-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009056707-A2 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210662-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | BRD4 75/4885GHSR 2882/4885POLB 3670/4885 |
| US-20110118280-A1 | INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | IDO2, IDO1, TPH2 | BRD4 75/4885GHSR 2882/4885POLB 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.